Literature DB >> 30578069

Malignant glaucoma after XEN45 implant.

S Montolío Marzo1, A Lanzagorta Aresti2, J M Davó Cabrera2, E A Alfonso Muñóz2, J V Piá Ludeña2, E Palacios Pozo2.   

Abstract

Minimally invasive glaucoma surgery for chronic open-angle glaucoma treatment tries to reduce the amount of chronic topical drug treatment, delaying invasive glaucoma surgery and diminishing the number of surgical complications. XEN45 uses subconjunctival drainage in order to reduce intraocular pressure. The report is presented of a patient following phacoemulsification, intraocular lens implantation and XEN45 implant. After four days acute malignant glaucoma was observed, with stage 3 athalamia requiring pars plana vitrectomy and secondary Ahmed valve implantation. The lower rate of complications due to minimally invasive glaucoma surgery has increased its use. Nevertheless, it is not free of severe adverse events, even requiring a multidisciplinary approach as in our malignant glaucoma report.
Copyright © 2018 Sociedad Española de Oftalmología. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Cirugía microinvasiva de glaucoma; Glaucoma maligno; Implante XEN; Malignant glaucoma; Minimally invasive glaucoma surgery; XEN implant

Mesh:

Year:  2018        PMID: 30578069     DOI: 10.1016/j.oftal.2018.10.023

Source DB:  PubMed          Journal:  Arch Soc Esp Oftalmol (Engl Ed)        ISSN: 2173-5794


  3 in total

Review 1.  Evaluating glaucoma surgeries in the MIGS context.

Authors:  Deepika Dhingra; Shibal Bhartiya
Journal:  Rom J Ophthalmol       Date:  2020 Apr-Jun

2.  Revisiting Results of Conventional Surgery: Trabeculectomy, Glaucoma Drainage Devices, and Deep Sclerectomy in the Era of MIGS.

Authors:  Shibal Bhartiya; Deepika Dhingra; Tarek Shaarawy
Journal:  J Curr Glaucoma Pract       Date:  2019 May-Aug

3.  Malignant glaucoma following gonioscopy-assisted transluminal trabeculotomy: a case report.

Authors:  Elena Bolletta; Danilo Iannetta; Antonio Moramarco; Luigi Fontana
Journal:  BMC Ophthalmol       Date:  2022-02-08       Impact factor: 2.209

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.